nach oben

Cardiovascular Toxicology

Erschienen in:

01.03.2011

Mechanistic Clues in the Cardioprotective Effect of Terminalia Arjuna Bark Extract in Isoproterenol-Induced Chronic Heart Failure in Rats

verfasst von: Adila Parveen, Rashmi Babbar, Sarita Agarwal, Anita Kotwani, Mohammad Fahim

Erschienen in: Cardiovascular Toxicology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The present study demonstrated prophylactic and therapeutic potential of Terminalia arjuna bark extract in isoproterenol (ISO)-induced chronic heart failure (CHF). Fifteen days after injection of ISO (85 mg/kg twice at an interval of 24 h, s.c), rats showed decline in maximal rate of rise and fall of left ventricular pressure (LV (dP/dt)_max and LV (dP/dt)_min), cardiac contractility index (LV (dP/dt)_max/LVP), cardiac output and rise in LV end-diastolic pressure. CHF rats showed a significant increase in serum creatine kinase isoenzyme-MB (CK-MB) and malondialdehyde levels, as well as fall in the activities of superoxide dismutase, reduced glutathione. Altered lipid profile and increased level of cytokine tumour necrosis factor-α (TNF-α) along with histological changes in heart were also observed in CHF rats. T. arjuna bark extract (500 mg/kg, p.o) treatment prior and 15 days after ISO injection significantly attenuated cardiac dysfunction and myocardial injury in CHF rats. Cardioprotective action of T. arjuna was comparable to fluvastatin, a synthetic drug. The results suggest that T. arjuna bark extract has a significant prophylactic and therapeutic beneficial effect on protection of heart against ISO-induced CHF possibly through maintaining endogenous antioxidant enzyme activities, inhibiting lipid peroxidation and cytokine levels.

Lloyd-Jones, D. M., Larson, M. G., Leip, E. P., Beiser, A., D’Agostino, R. B., Kannel, W. B., et al. (2002). Lifetime risk for developing congestive heart failure: The Framingham heart study. Circulation, 106, 3068–3072.CrossRefPubMed

Ho, K. K., Pinsky, J. L., Kannel, W. B., & Levy, D. (1993). The epidemiology of heart failure: The Framingham Study. Journal of the American College of Cardiology, 22, 6–13.CrossRef

Chae, C. U., Pfeffer, M. A., Glynn, R. J., Mitchell, G. F., Taylor, J. O., & Hennekens, C. H. (1999). Increased pulse pressure and risk of heart failure in the elderly. JAMA, 281, 634–639.CrossRefPubMed

Middlekauff, H. L. (1997). Mechanisms and implications of autonomic nervous system dysfunction in heart failure. Current Opinion in Cardiology, 12, 265–275.CrossRefPubMed

Zucker, I. H., & Wang, W. (1991). Reflex control of renal sympathetic nervous activity in heart failure. Herz, 16, 82–91.PubMed

DiBona, G. F., & Sawin, L. L. (1995). Increased renal nerve activity in cardiac failure: Arterial vs. cardiac baroreflex impairment. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 268, 112–116.

Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990). Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. New England Journal of Medicine, 323, 236–241.CrossRefPubMed

Landmesser, U., Spiekermann, S., Dikalov, S., Tatge, H., Wilke, R., Kohler, C., et al. (2002). Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: Role of xanthine-oxidase and extracellular superoxide dismutase. Circulation, 106, 3073–3078.CrossRefPubMed

Shah, A. M., & Channon, K. M. (2004). Free radicals and redox signalling in cardiovascular disease. Heart, 90, 486–487.CrossRefPubMed

10.

Giardano, F. J. (2005). Oxygen, oxidative stress, hypoxia, and heart failure. Journal of Clinical Investigation, 115, 500–508.

11.

Bozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., et al. (1998). Pathophysiologically relevant concentrations of tumour necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation, 97, 1382–1391.PubMed

12.

Cleland, J. G. F., Gemmell, I., Khand, A., & Body, A. (1999). Is the prognosis of heart failure improving? European Journal of Heart Failure, 1, 229–241.CrossRefPubMed

13.

Horwich, T. B., MacLellan, W. R., & Fonarow, G. C. (2004). Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. Journal of the American College of Cardiology, 43, 642–648.CrossRefPubMed

14.

Liao, J. K., & Laufs, U. (2005). Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology, 45, 89–118.CrossRefPubMed

15.

Grundy, S. M. (2005). The issue of statin safety: Where do we stand? Circulation, 111, 3016–3019.CrossRefPubMed

16.

Gotto, A. M. (2006). Statins, cardiovascular disease and drug safety. American Journal of Cardiology, 97, 3C–5C.PubMed

17.

Vaidya, A. B. (1994). Terminalia arjuna in cardiovascular therapy. The Journal of the Association of Physicians of India, 42, 281–282.PubMed

18.

Gupta, R., Singhal, S., Goyle, A., & Sharma, V. N. (2001). Antioxidant and hypocholesterolemic effects of Terminalia arjuna tree-bark powder: A randomized placebo-controlled trial. The Journal of the Association of Physicians of India, 49, 231–235.PubMed

19.

Dwivedi, S. (1994). Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary heart disease. The Journal of the Association of Physicians of India, 42, 287–289.PubMed

20.

Teerlink, J. R., Pfeffer, J. M., & Pfeffer, M. A. (1998). Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. Journal of Cardiac Failure, 4, 45–56.CrossRefPubMed

21.

Grimm, D., Elsner, D., Schunkert, H., Pfeffer, M., Griese, D., Bruckschlegel, G., et al. (1998). Development of heart failure following isoproterenol administration in the rat: Role of the renin- angiotensin system. Cardiovascular Research, 37, 91–100.CrossRefPubMed

22.

Hayashidani, S., Tsutsui, H., Shiomi, T., Suematsu, N., Kinugawa, S., Ide, T., et al. (2002). Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 105, 868–873.CrossRefPubMed

23.

Gauthaman, K., Maulik, M., Kumari, R., Manchanda, S. C., Dinda, A. K., & Maulik, S. K. (2001). Effect of chronic treatment with bark of Terminalia Arjuna: A study on the isolated ischemic-reperfused rat heart. Journal of Ethnopharmacology, 75, 197–201.CrossRefPubMed

24.

Bos, R., Mougenot, N., Findji, L., Médiani, O., Vanhoutte, P. M., & Lechat, P. (2005). Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. Journal of Cardiovascular Pharmacology, 45, 8–13.CrossRefPubMed

25.

Rona, G. (1985). Catecholamine cardiotoxicity. Journal of Molecular and Cellular Cardiology, 17, 291–306.CrossRefPubMed

26.

Yeager, J. C., & Iams, S. G. (1981). The hemodynamics of isoproterenol-induced cardiac failure in the rat. Circulatory Shock, 8, 151–163.PubMed

27.

Dhalla, K. S., Rupp, H., Beamish, R. E., & Dhalla, N. S. (1996). Mechanisms of alterations in cardiac membrane Ca²⁺ transport due to excess catecholamines. Cardiovascular Drugs and Therapy, 10, 231–238.CrossRefPubMed

28.

Singal, P. K., Beamich, R. E., & Dhalla, N. S. (1983). Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Advances in Experimental Medicine and Biology, 161, 391–440.PubMed

29.

Grimm, D., Holmer, S. R., Riegger, G. A. J., & Kromer, E. P. (1999). Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol- induced heart failure in the rat. Cardiovascular Pathology, 8, 315–323.CrossRefPubMed

30.

Balakumar, P., & Singh, M. (2006). The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic and Clinical Pharmacology and Toxicology, 99, 418–424.CrossRefPubMed

31.

Zhong, D. Z., Min, C. X., Siyu, S., Dan, D., & Hui, C. (2008). From neuroendocrine activation to intracardiac cyclic nucleotides in chronic heart failure of rats induced by isoproterenol. Journal of Chinese Clinical Medicine, 3, 601–608.

32.

Yeager, J. C., & Whitehurst, M. E. (1982). Verapamil prevents isoproterenol induced cardiac failure in rats. Life Sciences, 30, 299–306.CrossRefPubMed

33.

Teerlink, J. R., Pfeffer, J. M., & Pfeffer, M. A. (1994). Progressive ventricular remodeling in response to diffuse isoproterenol- induced myocardial necrosis in rats. Circulation Research, 75, 105–113.PubMed

34.

Nirmala, C., & Puvanakrishnan, R. (1996). Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Molecular and Cellular Biochemistry, 159, 85–93.CrossRefPubMed

35.

Zhou, R., Xu, Q., Zheng, P., Yan, L., Zheng, J., & Dai, G. (2008). Cardioprotective effect of fluvastatin on Isoproterenol-induced myocardial infarction in rat. European Journal of Pharmacology, 586, 244–250.CrossRefPubMed

36.

Kumar, S., Enjamoori, R., Jaiswal, A., Ray, R., Seth, S., & Maulik, S. K. (2009). Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). The Journal of Pharmacy and Pharmacology, 61, 1529–1536.PubMed

37.

Rajadurai, M., & Prince, P. S. M. (2006). Preventive effect of naringin on lipids, lipoproteins and lipid metabolic enzymes in isoproterenol-induced myocardial infarction in Wistar rats. Journal of Biochemical and Molecular Toxicology, 20, 191–197.CrossRefPubMed

38.

Mann, D. L. (2005). Targeted anticytokine therapy and the failing heart. American Journal of Cardiology, 95, 9–16.CrossRef

39.

Node, K., Fujita, M., Kitakaze, M., Hori, M., & Liao, J. K. (2003). Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation, 108, 839–843.CrossRefPubMed

Titel: Mechanistic Clues in the Cardioprotective Effect of Terminalia Arjuna Bark Extract in Isoproterenol-Induced Chronic Heart Failure in Rats
verfasst von: Adila Parveen
Rashmi Babbar
Sarita Agarwal
Anita Kotwani
Mohammad Fahim
Publikationsdatum: 01.03.2011
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 1/2011
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-010-9099-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Fatal Pulmonary Oedema Following Oxytocin Administration in a Pregnant Woman with Acute Myocardial Infarction

A Combination of Melatonin and Alpha Lipoic Acid has Greater Cardioprotective Effect than Either of them Singly Against Cadmium-Induced Oxidative Damage

Homocysteine Induces Oxidative–Nitrative Stress in Heart of Rats: Prevention by Folic Acid

Glutathione-Related Antioxidant Defense System in Elderly Patients Treated for Hypertension

Preventive Effects of Vanillic Acid on Lipids, Bax, Bcl-2 and Myocardial Infarct Size on Isoproterenol-Induced Myocardial Infarcted Rats: A Biochemical and In Vitro Study

Erratum to: A Combination of Melatonin and Alpha Lipoic Acid has Greater Cardioprotective Effect than Either of them Singly Against Cadmium-Induced Oxidative Damage